Principal Investigator
Olivier Rascol, MD, PhD
Toulouse University Hospital, France
- 3 trials
- 1 compound
Therapeutic focus
- Parkinson's Disease
- Parkinson Disease
- Multisystemic Atrophy
All trials (3)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT04006210 | Phase 3 | Active | ND0612 (levodopa/carbidopa continuous subcutaneous infusion) | NeuroDerm |
| NCT03439943 | Phase 2 | Completed | — | University Hospital, Toulouse |
| NCT01044992 | Unknown | Completed | — | University Hospital, Toulouse |
Compounds studied
Trial sites (40)
- Seville, Spain
- Farmington Hills, Michigan, United States
- Pécs, Hungary
- Chicago, Illinois, United States
- Krasnoyarsk, Russia
- Oviedo, Principality of Asturias, Spain
- Kansas City, Kansas, United States
- Innsbruck, Austria
- Siemianowice Śląskie, Poland
- Poltava, Ukraine
- Tomsk, Russia
- Boca Raton, Florida, United States
- Des Moines, Iowa, United States
- Los Angeles, California, United States
- New Brunswick, New Jersey, United States
- Lyon, France
- Madison, Wisconsin, United States
- Saint Petersburg, Russia
- Brno, Czechia
- Poitiers, France
- Nancy, France
- Torres Vedras, Portugal
- London, United Kingdom
- Besançon, France
- Clermont-Ferrand, France
- Winter Park, Florida, United States
- Warsaw, Poland
- Bratislava, Slovakia
- Alicante, Spain
- Limoges, France
- Strasbourg, France
- Honolulu, Hawaii, United States
- Cleveland, Ohio, United States
- Lille, France
- Kyiv, Ukraine
- Arcugnano, Italy
- Lodz, Poland
- Rouen, France
- Philadelphia, Pennsylvania, United States
- West Bloomfield, Michigan, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).